Fluoropolymer-MOF Hybrids with Switchable Hydrophilicity for 19 F MRI-Monitored Cancer Therapy
ACS Nano · 09.05.2023 · 17 (9) · 8483-8498
DOI: 10.1021/acsnano.3c00694 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACS Nano, online erschienen am 25.04.2023. Verfasst von Qiaoyun Wang und 11 weiteren Autor:innen. Beteiligte Einrichtung: Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, St Lucia, Queensland 4072, Australia. Hauptthemen laut MEDLINE: Metal-Organic Frameworks, Neoplasms, Nanoparticles. Die Arbeit wurde bisher 58-mal zitiert (Crossref) und nennt 62 Literaturangaben. Gefördert von: National Health and Medical Research Council, Australian Research Council.
Abstract (Originalsprache)
Cancer theranostics that combines cancer diagnosis and therapy is a promising approach for personalized cancer treatment. However, current theranostic strategies suffer from low imaging sensitivity for visualization and an inability to target the diseased tissue site with high specificity, thus hindering their translation to the clinic. In this study, we have developed a tumor microenvironment-responsive hybrid theranostic agent by grafting water-soluble, low-fouling fluoropolymers to pH-responsive zeolitic imidazolate framework-8 (ZIF-8) nanoparticles by surface-initiated RAFT polymerization. The conjugation of the fluoropolymers to ZIF-8 nanoparticles not only allows sensitive in vivo visualization of the nanoparticles by 19F MRI but also significantly prolongs their circulation time in the bloodstream, resulting in improved delivery efficiency to tumor tissue. The ZIF-8-fluoropolymer nanoparticles can respond to the acidic tumor microenvironment, leading to progressive degradation of the nanoparticles and release of zinc ions as well as encapsulated anticancer drugs. The zinc ions released from the ZIF-8 can further coordinate to the fluoropolymers to switch the hydrophilicity and reverse the surface charge of the nanoparticles. This transition in hydrophilicity and surface charge of the polymeric coating can reduce the "stealth-like" nature of the agent and enhance specific uptake by cancer cells. Hence, these hybrid nanoparticles represent intelligent theranostics with highly sensitive imaging capability, significantly prolonged blood circulation time, greatly improved accumulation within the tumor tissue, and enhanced anticancer therapeutic efficiency.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, St Lucia, Queensland 4072, Australia.
- Department of Polymer Science & Engineering, College of Chemistry & Chemical Engineering, Nanjing University, Nanjing 210093, PR China.
ORCID-Profile: Xu Zhen, Xiqun Jiang, Debra J Searles, Changkui Fu, Andrew K Whittaker
Förderung
- National Health and Medical Research Council
- Australian Research Council
Zitieren
APA
Wang, Q., Yu, Y., Chang, Y., Xu, X., Wu, M., Ediriweera, G. R., Peng, H., Zhen, X., Jiang, X., Searles, D. J., Fu, C., & Whittaker, A. K. (2023). Fluoropolymer-MOF Hybrids with Switchable Hydrophilicity for 19 F MRI-Monitored Cancer Therapy. ACS Nano, 17(9), 8483-8498. https://doi.org/10.1021/acsnano.3c00694
Vancouver
Wang Q, Yu Y, Chang Y, Xu X, Wu M, Ediriweera GR, et al. Fluoropolymer-MOF Hybrids with Switchable Hydrophilicity for 19 F MRI-Monitored Cancer Therapy. ACS Nano. 2023;17(9):8483-8498. doi:10.1021/acsnano.3c00694
BibTeX
@article{Wang2023,
author = {Wang, Qiaoyun and Yu, Ye and Chang, Yixin and Xu, Xin and Wu, Min and Ediriweera, Gayathri R and Peng, Hui and Zhen, Xu and Jiang, Xiqun and Searles, Debra J and Fu, Changkui and Whittaker, Andrew K},
title = {Fluoropolymer-MOF Hybrids with Switchable Hydrophilicity for 19 F MRI-Monitored Cancer Therapy},
journal = {ACS Nano},
year = {2023},
volume = {17},
number = {9},
pages = {8483--8498},
doi = {10.1021/acsnano.3c00694}
}
EUVIMED